- Home
- DLTH vs EQ Comparison
DLTH vs EQ Comparison
Compare DLTH & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLTH
- EQ
- Stock Information
- Founded
- DLTH 1989
- EQ 2017
- Country
- DLTH United States
- EQ United States
- Employees
- DLTH N/A
- EQ N/A
- Industry
- DLTH Clothing/Shoe/Accessory Stores
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- DLTH Consumer Discretionary
- EQ Health Care
- Exchange
- DLTH Nasdaq
- EQ Nasdaq
- Market Cap
- DLTH 80.4M
- EQ 67.9M
- IPO Year
- DLTH 2015
- EQ 2018
- Fundamental
- Price
- DLTH $2.31
- EQ $1.82
- Analyst Decision
- DLTH Hold
- EQ Buy
- Analyst Count
- DLTH 1
- EQ 3
- Target Price
- DLTH $2.75
- EQ $3.00
- AVG Volume (30 Days)
- DLTH 27.0K
- EQ 23.5M
- Earning Date
- DLTH 09-04-2025
- EQ 08-14-2025
- Dividend Yield
- DLTH N/A
- EQ N/A
- EPS Growth
- DLTH N/A
- EQ N/A
- EPS
- DLTH N/A
- EQ N/A
- Revenue
- DLTH $612,649,000.00
- EQ $16,553,000.00
- Revenue This Year
- DLTH N/A
- EQ N/A
- Revenue Next Year
- DLTH $0.55
- EQ N/A
- P/E Ratio
- DLTH N/A
- EQ N/A
- Revenue Growth
- DLTH N/A
- EQ N/A
- 52 Week Low
- DLTH $1.58
- EQ $0.27
- 52 Week High
- DLTH $4.50
- EQ $2.26
- Technical
- Relative Strength Index (RSI)
- DLTH 55.36
- EQ 74.99
- Support Level
- DLTH $2.08
- EQ $1.70
- Resistance Level
- DLTH $2.33
- EQ $2.23
- Average True Range (ATR)
- DLTH 0.11
- EQ 0.33
- MACD
- DLTH 0.00
- EQ 0.08
- Stochastic Oscillator
- DLTH 74.07
- EQ 70.27
About DLTH Duluth Holdings Inc. Class B
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.